한글목차

BAY3401016은 세마포린-3A("Sema3A")를 표적으로 하는 단클론항체("mAb")입니다. 액틴 세포 골격, 특히 포도사이트의 변화는 알포트 증후군의 주요 병태 생리학적 특징인 Sema3A는 상해를 입은 인간의 신장에서 발현이 상승하고 급성 및 만성 신장병의 개발과 진행에 관여하고 있습니다. 난청에도 좋은 영향을 줄 수 있으며, 질병의 진행과 말기 신장 질환의 발병을 지연시키는 것을 목적으로 하고 있습니다.

본 보고서에서는 주요 7개국의 BAY3401016 시장에 대해 조사했으며, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장 BAY3401016 알포트 증후군 개요

• 제품 상세
• 임상 개발
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 BAY3401016 시장 평가

• 알포트 증후군에서 BAY3401016 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"BAY3401016 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about BAY3401016 for Alport syndrome in the seven major markets. A detailed picture of the BAY3401016 for Alport syndrome in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the BAY3401016 for Alport syndrome. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BAY3401016 market forecast analysis for Alport syndrome in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Alport syndrome.

Drug Summary:

BAY3401016 is a monoclonal antibody ("mAb") targeting the protein Semaphorin-3A ("Sema3A"). Semaphorin-3A ("Sema3A") is an extracellular guidance protein and a well-known regulator of the actin cytoskeleton. Alterations of the actin cytoskeleton, particularly of podocytes, are a key pathophysiological feature of Alport syndrome. Sema3A is upregulated in injured human kidneys and implicated in the development and progression of acute and chronic kidney diseases. The drug is being developed as a potential first-to-market treatment for Alport syndrome, aiming to delay disease progression and the onset of end-stage renal disease, with a potentially positive impact on hearing loss.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the BAY3401016 description, mechanism of action, dosage and administration, research and development activities in Alport syndrome.
• Elaborated details on BAY3401016 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the BAY3401016 research and development activities in Alport syndrome across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around BAY3401016.
• The report contains forecasted sales of BAY3401016 for Alport syndrome till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Alport syndrome.
• The report also features the SWOT analysis with analyst views for BAY3401016 in Alport syndrome.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BAY3401016 Analytical Perspective by DelveInsight

• In-depth BAY3401016 Market Assessment

This report provides a detailed market assessment of BAY3401016 for Alport syndrome in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2029 to 2032.

• BAY3401016 Clinical Assessment

The report provides the clinical trials information of BAY3401016 for Alport syndrome covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Alport syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BAY3401016 dominance.
• Other emerging products for Alport syndrome are expected to give tough market competition to BAY3401016 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BAY3401016 in Alport syndrome.
• Our in-depth analysis of the forecasted sales data of BAY3401016 from 2029 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BAY3401016 in Alport syndrome.

Key Questions:

• What is the product type, route of administration and mechanism of action of BAY3401016?
• What is the clinical trial status of the study related to BAY3401016 in Alport syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BAY3401016 development?
• What are the key designations that have been granted to BAY3401016 for Alport syndrome?
• What is the forecasted market scenario of BAY3401016 for Alport syndrome?
• What are the forecasted sales of BAY3401016 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to BAY3401016 for Alport syndrome?
• Which are the late-stage emerging therapies under development for the treatment of Alport syndrome?

Table of Contents

1. Report Introduction

2. BAY3401016 Overview in Alport syndrome

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. BAY3401016 Market Assessment

• 5.1. Market Outlook of BAY3401016 in Alport syndrome
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of BAY3401016 in the 7MM for Alport syndrome
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of BAY3401016 in the United States for Alport syndrome
  • 5.3.2. Market Size of BAY3401016 in Germany for Alport syndrome
  • 5.3.3. Market Size of BAY3401016 in France for Alport syndrome
  • 5.3.4. Market Size of BAY3401016 in Italy for Alport syndrome
  • 5.3.5. Market Size of BAY3401016 in Spain for Alport syndrome
  • 5.3.6. Market Size of BAY3401016 in the United Kingdom for Alport syndrome
  • 5.3.7. Market Size of BAY3401016 in Japan for Alport syndrome

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options